Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by AstraZeneca
< Previous
1
2
3
4
5
6
Next >
Alexion advances commitment to transform patient outcomes in rare neurological diseases at AAN 2023
March 02, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca and Merck present final results of key secondary overall survival endpoint from Phase III PROpel trial at ASCO GU Cancers Symposium
February 16, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
TEZSPIRE® approved for self-administration in the US with a new pre-filled pen
February 02, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.
January 23, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AIRSUPRA™ (PT027) approved in the US for asthma
January 11, 2023
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca Awards $4M to Nonprofit Organizations to Advance Health Equity
December 13, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Camizestrant Significantly Delayed Disease Progression in Advanced ER-Positive Breast Cancer, Adding at Least 3.5 Months Benefit Versus FASLODEX® (fulvestrant)
December 08, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Capivasertib Plus FASLODEX® (fulvestrant) Reduced the Risk of Disease Progression or Death by 40% Versus FASLODEX in Advanced HR-Positive Breast Cancer
December 08, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Achieved Statistically Significant Overall Survival, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Breast cancer in DESTINY-Breast03
December 07, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca Showcases Strength of Hematology Portfolio and Pipeline Across Multiple Hard-to-Treat Conditions at ASH 2022
November 30, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca Aims to Redefine Breast Cancer Care With New Data Across the Treatment Spectrum At SABCS 2022
November 22, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI and IMJUDO with chemotherapy approved in the US for patients with metastatic non-small cell lung cancer
November 11, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca EVUSHELD Named on TIME’s List of the Best Inventions of 2022
November 10, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma
November 09, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX® (fulvestrant) in SERENA-2 Phase II Trial in Advanced ER-positive Breast Cancer
October 26, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
Capivasertib plus FASLODEX® (fulvestrant) significantly improved progression-free survival vs. FASLODEX in CAPItello-291 Phase III trial in advanced HR-positive breast cancer
October 26, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMJUDO® (tremelimumab) in Combination With IMFINZI® (durvalumab) Approved in the US for Patients With Unresectable Liver Cancer
October 24, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca Announces Winners of Fourth Annual Cancer Community Awards
October 20, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca Partners with Jeff Bridges, Kumail Nanjiani, and Emily V. Gordon to Educate the Immunocompromised Community about Added Protection Against COVID-19
September 15, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI® (durvalumab) plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-up
September 12, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer
September 11, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI® (durvalumab) and tremelimumab with chemotherapy demonstrated sustained survival benefit in metastatic non-small cell lung cancer, nearly doubling the number of patients alive after three years vs. chemotherapy
September 11, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
TAGRISSO® (osimertinib) demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer
September 11, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
LYNPARZA® (olaparib) in Combination with Bevacizumab, and as a Monotherapy, Demonstrates Clinically Meaningful Survival Benefit in 1st-Line Advanced Ovarian Cancer Across Two Phase III Trials
September 09, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
IMFINZI® (durvalumab) Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Patients with Advanced Biliary Tract Cancer
September 05, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
New data show FARXIGA significantly lowers the risk of cardiovascular death in patients with heart failure
August 27, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial
August 27, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
AstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022
August 24, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
LYNPARZA® (olaparib) in combination with abiraterone granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer
August 16, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
August 12, 2022
From
AstraZeneca
Via
Business Wire
Tickers
AZN
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.